Résumé

Objective: To evaluate the survival of breast adenocarcinoma based on molecular subtype. Methodology: This was a retrospective, monocentric cohort study with descriptive and analytical aims, conducted over a two-year period from January 1, 2019, to December 31, 2021, at the Oncology Department of Treichville University Hospital. This department manages adult patients with solid tumors. The study included all female patients with histologically confirmed breast adenocarcinoma and available immunohistochemistry results. Results: A total of 250 patients were included. The median age was 48 years (range: 31–74 years). A family history of breast cancer was found in 10% of cases. The most common initial stage was locally advanced disease, observed in 64.8% of patients. The most prevalent molecular subtype was triple-negative, representing 50.8% of cases. Post-treatment evaluation based on RECIST criteria showed disease progression across all molecular subtypes in 58.8% of cases. The median progression-free survival (PFS) was 12 months for triple-negative adenocarcinomas, 18 months for luminal subtypes, and 31 months for HER2-positive subtypes. The overall median survival, regardless of stage or molecular profile, was 19 months, with a 2-year overall survival rate of 35%. Conclusion: In addition to classical histology, immunohistochemistry enabled the identification of molecular subtypes, namely luminal A and B, HER2-enriched, and triple-negative. Patients with HER2-enriched tumors had a better prognosis.

Mot-clés :

Breast Cancer; Adenocarcinoma; Molecular Subtype; Triple-Negative; Her2; Luminal; Immunohistochemistry; Survival